Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Toffoli

Showing results (11-20 of 265) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 16, 2009
C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisationElena De Mattia, Giuseppe Toffoli
Pharmacogenomics|February 15, 2018
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategyRossana Roncato, Erika Cecchin, Giuseppe Toffoli
Pharmacology & Therapeutics|June 15, 2010
Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agentsMichele Visentin, Paola Biason, Giuseppe Toffoli
Journal of Immunology Research|August 8, 2017
Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer CellsMarica Garziera, Lucia Scarabel, Giuseppe Toffoli
ACS Medicinal Chemistry Letters|June 18, 2014
Fluorescent carbon nanoparticles in medicine for cancer therapyVinit Kumar, Giuseppe Toffoli, Flavio Rizzolio
Expert Opinion on Drug Metabolism & Toxicology|January 21, 2016
Nuclear receptors and drug metabolism for the personalization of cancer therapyErika Cecchin, Elena De Mattia, Giuseppe Toffoli
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 2, 2015
Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapyElena De Mattia, Erika Cecchin, Giuseppe Toffoli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?Giampietro Gasparini, Mario R D'Andrea, Giuseppe Toffoli
Cancers|September 10, 2021
Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular CarcinomaMelissa Borgia, Michele Dal Bo, Giuseppe Toffoli
Pharmacogenomics|November 29, 2011
Research highlights. Protein kinase D3 is the genetic sensitizer of RAF inhibitor RAF265 in melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Pageof 27

Showing results (11-20 of 265) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|January 16, 2009
C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisationElena De Mattia, Giuseppe Toffoli
Pharmacogenomics|February 15, 2018
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategyRossana Roncato, Erika Cecchin, Giuseppe Toffoli
Pharmacology & Therapeutics|June 15, 2010
Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agentsMichele Visentin, Paola Biason, Giuseppe Toffoli
Journal of Immunology Research|August 8, 2017
Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer CellsMarica Garziera, Lucia Scarabel, Giuseppe Toffoli
ACS Medicinal Chemistry Letters|June 18, 2014
Fluorescent carbon nanoparticles in medicine for cancer therapyVinit Kumar, Giuseppe Toffoli, Flavio Rizzolio
Expert Opinion on Drug Metabolism & Toxicology|January 21, 2016
Nuclear receptors and drug metabolism for the personalization of cancer therapyErika Cecchin, Elena De Mattia, Giuseppe Toffoli
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 2, 2015
Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapyElena De Mattia, Erika Cecchin, Giuseppe Toffoli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?Giampietro Gasparini, Mario R D'Andrea, Giuseppe Toffoli
Cancers|September 10, 2021
Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular CarcinomaMelissa Borgia, Michele Dal Bo, Giuseppe Toffoli
Pharmacogenomics|November 29, 2011
Research highlights. Protein kinase D3 is the genetic sensitizer of RAF inhibitor RAF265 in melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Pageof 27